ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is Birchview Capital LP's 3rd Largest Position

Birchview Capital LP reduced its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 15.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 338,400 shares of the biopharmaceutical company's stock after selling 62,000 shares during the period. ACADIA Pharmaceuticals makes up about 5.0% of Birchview Capital LP's investment portfolio, making the stock its 3rd biggest position. Birchview Capital LP owned approximately 0.20% of ACADIA Pharmaceuticals worth $6,210,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of ACAD. Vanguard Group Inc. lifted its stake in shares of ACADIA Pharmaceuticals by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 13,947,640 shares of the biopharmaceutical company's stock valued at $255,939,000 after buying an additional 104,444 shares in the last quarter. First Trust Advisors LP boosted its position in shares of ACADIA Pharmaceuticals by 27.0% during the fourth quarter. First Trust Advisors LP now owns 2,700,125 shares of the biopharmaceutical company's stock worth $49,547,000 after acquiring an additional 574,251 shares during the last quarter. SG Americas Securities LLC boosted its position in shares of ACADIA Pharmaceuticals by 380.3% during the fourth quarter. SG Americas Securities LLC now owns 2,483,731 shares of the biopharmaceutical company's stock worth $45,576,000 after acquiring an additional 1,966,607 shares during the last quarter. Norges Bank purchased a new position in ACADIA Pharmaceuticals during the fourth quarter valued at $25,555,000. Finally, Renaissance Technologies LLC boosted its holdings in shares of ACADIA Pharmaceuticals by 204.2% during the 4th quarter. Renaissance Technologies LLC now owns 1,226,533 shares of the biopharmaceutical company's stock valued at $22,507,000 after purchasing an additional 823,333 shares during the last quarter. Institutional investors own 96.71% of the company's stock.

Insiders Place Their Bets

In other news, EVP Mark C. Schneyer sold 2,708 shares of the business's stock in a transaction on Tuesday, April 8th. The shares were sold at an average price of $14.82, for a total transaction of $40,132.56. Following the sale, the executive vice president now directly owns 59,456 shares of the company's stock, valued at $881,137.92. The trade was a 4.36 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Elizabeth A. Garofalo sold 4,919 shares of ACADIA Pharmaceuticals stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $18.23, for a total value of $89,673.37. Following the sale, the director now directly owns 17,595 shares of the company's stock, valued at approximately $320,756.85. This represents a 21.85 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 14,169 shares of company stock valued at $242,686. 28.30% of the stock is currently owned by corporate insiders.

ACADIA Pharmaceuticals Trading Up 0.2 %

Shares of ACAD traded up $0.03 during midday trading on Thursday, hitting $14.63. 687,233 shares of the company's stock traded hands, compared to its average volume of 2,176,552. ACADIA Pharmaceuticals Inc. has a 1 year low of $13.40 and a 1 year high of $20.68. The firm's fifty day moving average is $16.32 and its 200-day moving average is $16.92. The stock has a market capitalization of $2.44 billion, a price-to-earnings ratio of 18.76 and a beta of 0.54.

Analyst Ratings Changes

Several equities analysts have weighed in on ACAD shares. Cantor Fitzgerald restated an "overweight" rating and set a $28.00 price target on shares of ACADIA Pharmaceuticals in a report on Thursday, February 27th. StockNews.com upgraded shares of ACADIA Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday, March 8th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of ACADIA Pharmaceuticals in a research report on Tuesday, February 11th. They set a "hold" rating and a $22.00 target price on the stock. HC Wainwright reiterated a "buy" rating and issued a $27.00 price target on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. Finally, UBS Group lowered their price objective on ACADIA Pharmaceuticals from $25.00 to $22.00 and set a "buy" rating for the company in a research note on Monday. Eight analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $23.87.

ACADIA Pharmaceuticals Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.